Posted by Michael Wonder on 28 Apr 2022
SQZ Biotechnologies receives FDA fast track designation for its lead cell therapy candidate for the treatment of HPV16 positive tumours
27 April 2022 - Designation Creates Potential to Bring Important New Therapy to Patients Earlier.
SQZ Biotechnologies today announced that the U.S. FDA has granted fast track designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16 positive advanced or metastatic solid tumours.
